Compounds

ABSTRACT

The present invention relates to compounds of formula (I): 
                         
wherein R 1  and R 2  are as defined herein. In certain embodiments, the compounds of the present invention are inhibitors of RORγt and are useful in the treatment of diseases and conditions mediated by RORγt.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of, and claims priority to,International Application No. PCT/GB2015/053184, filed Oct. 23, 2015,which claims priority to Great Britain Application No. GB1419015.1,filed Oct. 24, 2014, the contents of all of which are herebyincorporated herein by reference in their entireties.

The present invention relates to compounds which are inhibitors ofretinoic acid-related orphan receptor γt (RORγt) activity and which aretherefore of use in the treatment of immune-mediated diseases, includingautoimmune diseases, and inflammatory conditions. The invention alsorelates to methods of preparing the compounds and pharmaceuticalcompositions containing them.

RORγt is known to play a central role in immune system development sinceit both regulates development of T cells in the thymus anddifferentiation of effector T cells in the periphery. RORγt is alsorequired for the differentiation of pro-inflammatory Th17 cells (Ivanovet al, Cell, 126, 1121-1133, 2006). Small molecule inhibitors of RORγtinhibit the differentiation of human Th17 cells in vitro and reduce Th17cell numbers and disease activity in animal models of autoimmune disease(Huh et al., 2011, Nature 472:486-490). RORγ is also involved in thedevelopment of other pathogenic immune cells include type 3 innatelymphoid cells (ILCs). Interleukin 23 activates ILCs in aRORγt-dependent manner (Luci et al., 2008; Buonocore et al., 2010,Nature 464:1371-1375) and these cells contribute to experimental colitisand are present in the inflamed intestine of patients with IBD(Buonocore et al., 2010; Geremia et al., 2011, J Exp Med 208:1127-1133).

It has been demonstrated that Th17 cells and their products, IL17A,IL-17F, IL-21 and IL-22, are associated with the pathology of variousinflammatory and autoimmune disorders, in particular, chronicinflammatory diseases such as psoriasis, rheumatoid arthritis, multiplesclerosis, inflammatory bowel diseases, ankylosing spondylitis, systemiclupus erythematosus and lung diseases including severe asthma, chronicobstructive pulmonary disease and cystic fibrosis.

Some antagonists of RORγt are known and, for example, WO 2012/106995A1,WO 2014/026327, WO 2014/026328, WO 2014/026329, WO 2014/026330, WO2014/028589, WO 2014/028592, WO 2014/028597 and WO 2014/028600 allrelate to compounds which are said to have RORγt inhibiting activity.

The present invention relates to novel antagonists of RORγt which are ofuse in the treatment and prevention of these and related conditions.

In a first aspect of the present invention there is provided a compoundof general formula (I):

whereinR¹ is H, F or OH;R² is C₁₋₃ alkyl, C₁₋₃ haloalkyl or cyclopropyl;provided that when R¹ is H, R³ is C₁₋₃ haloalkyl;or a pharmaceutically or veterinarily acceptable salt, solvate orhydrate thereof or a deuterated or tritiated variant thereof, includingall stereoisomers.

The compounds of the invention are inhibitors of RORγt and are thereforeof use in the treatment and prevention of a number of inflammatory andautoimmune conditions.

WO 2015/087234 relates to RORγt which are very similar to the compoundsof the present invention. However, the present inventors havedemonstrated that by careful selection of substituents, it is possibleto improve the activity of these compounds.

In the present specification, except where the context requiresotherwise due to express language or necessary implication, the word“comprises”, or variations such as “comprises” or “comprising” is usedin an inclusive sense i.e. to specify the presence of the statedfeatures but not to preclude the presence or addition of furtherfeatures in various embodiments of the invention.

In the present specification the term “C₁₋₃ alkyl” refers to a fullysaturated straight or branched hydrocarbon chain having from 1 to 3carbon atoms. Examples include methyl, ethyl, n-propyl, isopropyl,t-butyl, n-hexyl.

The term “C₃₋₈ cycloalkyl” refers to a fully saturated hydrocarbon ringhaving from 3 to 8 carbon atoms. Examples include cyclopropyl,cyclopentyl and cyclohexyl.

The term “C₁₋₈ haloalkyl” refers to a C₁₋₈ alkyl group as defined abovein which one or more hydrogen atoms are replaced by halo atoms.Haloalkyl groups may have any number of halo substituents from 1 toperhalosubstituted. Examples include chloromethyl, trifluoromethyl,1-bromoethyl, 1,1,2,2-tetrafluoroethyl etc.

In the present specification, “halo” refers to fluoro, chloro, bromo oriodo.

The terms “deuterated variant” and “tritiated variant” referrespectively to compounds in which one or more of the hydrogen atoms isa deuterium or is a tritium atom.

Appropriate pharmaceutically and veterinarily acceptable salts of thecompounds of general formulae (I) include basic addition salts such assodium, potassium, calcium, aluminium, zinc, magnesium and other metalsalts as well as choline, diethanolamine, ethanolamine, ethyl diamine,megulmine and other well-known basic addition salts as summarised inPaulekuhn et al., (2007) J. Med. Chem. 50: 6665-6672 and/or known tothose skilled in the art.

Salts which are not pharmaceutically or veterinarily acceptable maystill be valuable as intermediates.

In some suitable compounds of general formula (I), R¹ is H.

In other suitable compounds of general formula (I), R¹ is F. Suitably,in this case the F is positioned at the 3-position of the phenyl ring(i.e. adjacent to the atom which is linked to the indole ring system).

In yet other suitable compounds of general formula (I), R¹ is OH.Suitably the OH is positioned at the 2-position of the phenyl ring (i.e.adjacent to the C(O)OH group).

In the compounds of general formula (I), R² is suitably C₁₋₂ alkyl, C₁₋₂haloalkyl or cyclopropyl.

More suitably, R² is trifluoromethyl or cyclopropyl, especiallytrifluoromethyl.

Some particularly suitable compounds of the invention include:

-   4-{3-[2-chloro-6-(trifluoromethyl)benzoyl]-7-fluoro-1H-indol-1-yl}benzoic    acid (Compound 1);-   4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]-7-fluoro-1H-indol-1-yl]-2-hydroxy-benzoic    acid (Compound 2);-   4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]-7-fluoro-1H-indol-1-yl]-3-fluoro-benzoic    acid (Compound 3);-   4-[3-(2-chloro-6-cyclopropyl-benzoyl)-7-fluoro-1H-indol-1-yl]-3-fluoro-benzoic    acid (Compound 4);

C₁₋₆ alkyl and benzyl esters thereof; and, their pharmaceutically orveterinarily acceptable salts, solvates or hydrates or a deuterated ortritiated variant thereof, including all stereoisomers.

Compounds of general formula (I) may be prepared from compounds ofgeneral formula (II):

wherein R¹ is as defined for general formula (I);by reaction with a compound of general formula (III):

wherein R² and R³ are as defined for general formula (I) and X is aleaving group, for example halo and particularly chloro.

The reaction may be conducted in an aqueous solvent and in the presenceof a base, which may be, for example, a quaternary nitrogen compound oran organometallic reagent such as dimethylaluminium chloride.

Suitably the reaction will be carried out under an inert atmosphere, forexample under nitrogen.

Compounds of general formulae (II) and (III) are known and are readilyavailable or may be prepared by methods known to those of skill in theart.

The compounds of the present invention are useful in the treatment ofdiseases and conditions mediated by RORγt, in particular inflammatoryand autoimmune diseases.

Therefore, in a further aspect of the invention, there is provided acompound of general formula (I) as defined above for use in medicine,particularly for use in the treatment or prevention of diseases andconditions mediated by RORγt, in particular inflammatory and autoimmunediseases.

More specifically, there is provided a compound of general formula (I)as defined above for use in the treatment or prevention of asthma,chronic obstructive pulmonary disease (COPD), bronchitis, allergicdiseases, such as allergic rhinitis and atopic dermatitis, cysticfibrosis, lung allograft rejection, multiple sclerosis, rheumatoidarthritis, juvenile rheumatoid arthritis, osteoarthritis, ankylosingspondylitis, systemic lupus erythematosus, psoriasis, Hashimoto'sdisease, pancreatitis, autoimmune diabetes, autoimmune ocular disease,ulcerative colitis, Crohn's disease, inflammatory bowel disease (IBD),Sjorgen's syndrome, Behcet's disease, optic neuritis, type I diabetes,neuromyelitis optica, myasthenia gravis, uveitis, Guillain-Barresyndrome, psoriatic arthritis, Graves' disease or scleritis. In afurther aspect, there is provided the use of a compound of generalformula (I) in the preparation of an agent for the treatment orprevention of asthma, chronic obstructive pulmonary disease (COPD),bronchitis, allergic diseases, such as allergic rhinitis and atopicdermatitis, cystic fibrosis, lung allograft rejection, multiplesclerosis, rheumatoid arthritis, juvenile rheumatoid arthritis,osteoarthritis, ankylosing spondylitis, systemic lupus erythematosus,psoriasis, Hashimoto's disease, pancreatitis, autoimmune diabetes,autoimmune ocular disease, ulcerative colitis, Crohn's disease,inflammatory bowel disease (IBD), Sjorgen's syndrome, Behcet's disease,optic neuritis, type I diabetes, neuromyelitis optica, myastheniagravis, uveitis, Guillain-Barre syndrome, psoriatic arthritis, Graves'disease or scleritis.

In addition, the invention provides a method for the treatment orprevention of a disease or condition selected from the group consistingof asthma, chronic obstructive pulmonary disease (COPD), bronchitis,allergic diseases, such as allergic rhinitis and atopic dermatitis,cystic fibrosis, lung allograft rejection, multiple sclerosis,rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis,ankylosing spondylitis, systemic lupus erythematosus, psoriasis,Hashimoto's disease, pancreatitis, autoimmune diabetes, autoimmuneocular disease, ulcerative colitis, Crohn's disease, inflammatory boweldisease (IBD), Sjorgen's syndrome, Behcet's disease, optic neuritis,type I diabetes, neuromyelitis optica, myasthenia gravis, uveitis,Guillain-Barre syndrome, psoriatic arthritis, Graves' disease orscleritis, the method comprising administering to a patient in need ofsuch treatment and effective amount of a compound of general formula(I).

The compounds of the present invention will generally be administered toa patient in a suitable pharmaceutical formulation. Therefore, in afurther aspect of the invention there is provided a pharmaceutical orveterinary composition comprising a compound of general formula (I)together with a pharmaceutically or veterinarily acceptable excipient orcarrier. Other active materials may also be present, as may beconsidered appropriate or advisable for the disease or condition beingtreated or prevented.

The carrier, or, if more than one be present, each of the carriers, mustbe acceptable in the sense of being compatible with the otheringredients of the formulation and not deleterious to the recipient.

The formulations include those suitable for oral, rectal, nasal,bronchial (inhaled), topical (including eye drops, buccal andsublingual), vaginal or parenteral (including subcutaneous,intramuscular, intravenous and intradermal) administration and may beprepared by any methods well known in the art of pharmacy.

The route of administration will depend upon the condition to be treatedbut preferred compositions are formulated for oral, nasal, bronchial ortopical administration.

The composition may be prepared by bringing into association the abovedefined active agent with the carrier. In general, the formulations areprepared by uniformly and intimately bringing into association theactive agent with liquid carriers or finely divided solid carriers orboth, and then if necessary shaping the product. The invention extendsto methods for preparing a pharmaceutical composition comprisingbringing a compound of general formula (I) conjunction or associationwith a pharmaceutically or veterinarily acceptable carrier or vehicle.

Formulations for oral administration in the present invention may bepresented as: discrete units such as capsules, sachets or tablets eachcontaining a predetermined amount of the active agent; as a powder orgranules; as a solution or a suspension of the active agent in anaqueous liquid or a non-aqueous liquid; or as an oil-in-water liquidemulsion or a water in oil liquid emulsion; or as a bolus etc.

For compositions for oral administration (e.g. tablets and capsules),the term “acceptable carrier” includes vehicles such as commonexcipients e.g. binding agents, for example syrup, acacia, gelatin,sorbitol, tragacanth, polyvinylpyrrolidone (Povidone), methylcellulose,ethylcellulose, sodium carboxymethylcellulose,hydroxypropylmethylcellulose, sucrose and starch; fillers and carriers,for example corn starch, gelatin, lactose, sucrose, microcrystallinecellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride andalginic acid; and lubricants such as magnesium stearate, sodium stearateand other metallic stearates, glycerol stearate, stearic acid, siliconefluid, talc waxes, oils and colloidal silica. Flavouring agents such aspeppermint, oil of wintergreen, cherry flavouring and the like can alsobe used. It may be desirable to add a colouring agent to make the dosageform readily identifiable. Tablets may also be coated by methods wellknown in the art. A tablet may be made by compression or moulding,optionally with one or more accessory ingredients. Compressed tabletsmay be prepared by compressing in a suitable machine the active agent ina free flowing form such as a powder or granules, optionally mixed witha binder, lubricant, inert diluent, preservative, surface-active ordispersing agent. Moulded tablets may be made by moulding in a suitablemachine a mixture of the powdered compound moistened with an inertliquid diluent. The tablets may optionally be coated or scored and maybe formulated so as to provide slow or controlled release of the activeagent.

Other formulations suitable for oral administration include lozengescomprising the active agent in a flavoured base, usually sucrose andacacia or tragacanth; pastilles comprising the active agent in an inertbase such as gelatin and glycerin, or sucrose and acacia; andmouthwashes comprising the active agent in a suitable liquid carrier.

For topical application to the skin, compounds of general formula (I)may be made up into a cream, ointment, jelly, solution or suspensionetc. Cream or ointment formulations that may be used for the drug areconventional formulations well known in the art, for example, asdescribed in standard text books of pharmaceutics such as the BritishPharmacopoeia.

Compounds of general formula (I) may be used for the treatment of therespiratory tract by nasal, bronchial or buccal administration of, forexample, aerosols or sprays which can disperse the pharmacologicalactive ingredient in the form of a powder or in the form of drops of asolution or suspension. Pharmaceutical compositions withpowder-dispersing properties usually contain, in addition to the activeingredient, a liquid propellant with a boiling point below roomtemperature and, if desired, adjuncts, such as liquid or solid non-ionicor anionic surfactants and/or diluents. Pharmaceutical compositions inwhich the pharmacological active ingredient is in solution contain, inaddition to this, a suitable propellant, and furthermore, if necessary,an additional solvent and/or a stabiliser. Instead of the propellant,compressed air can also be used, it being possible for this to beproduced as required by means of a suitable compression and expansiondevice.

Parenteral formulations will generally be sterile.

Typically, the dose of the compound will be about 0.01 to 100 mg/kg; soas to maintain the concentration of drug in the plasma at aconcentration effective to inhibit RORγt.

Compounds of general formula (I) may be used in combination with one ormore other active agents which are useful in the treatment of thediseases and conditions listed above. These active agents may be otherRORγt inhibitors but will more usually have a different mechanism ofaction.

Therefore the pharmaceutical composition may also contain one or more ofsuch additional active agents.

There is also provided a combined preparation comprising a compound offormula (I) together with an additional active ingredient, forsimultaneous, sequential or separate use in the treatment of a diseaseor condition mediated by RORγt as described above.

The invention will now be described in greater detail with reference tothe following non-limiting examples.

In the examples, the following abbreviations are used.

DCM Dichloromethane DMSO Dimethylsulfoxide EtOAc Ethyl acetate FCC Flashcolumn chromatography LCMS Liquid chromatography-mass spectrometry MeCNAcetonitrile rt Room temperature THF Tetrahydrofuran tr Retention timeGeneral Experimental Details for all Examples Except Comparative Example1:

Reverse phase HPLC was performed with a Waters FractionLynx system withintegrated MS detection. Chromatographic conditions; Gradient 5-95% ACNin 0.1M HCO2H, pH3. Column: Waters Sunfire C18 ODB 5μ 19×150 mm.

Reverse phase HPLC on SCF was performed with a Waters Prep100 SCF systemwith integrated MS detection. Chromatographic conditions; MeOH/NH3 20mM, Column: Phenomenex Luna Hilic 5μ, 30×250 mm.

Analytical LC-MS experiments were performed using a Waters Acquitysystem combined with a Waters Xevo Q-ToF Mass or a Shimadzu 2010EV UPLCsystem in ESI mode. Chromatographic conditions: gradient 5-90% ACN,pH10. Column: Waters Acquity BEH C18 1.7μ 2.1×50 mm.

NMR spectra were recorded on a Bruker Avance, Avance II or Avance IIIspectrometer at a proton frequency of 300, 400, 500 or 600 MHz. Thecentral peaks of chloroform-δ (H 7.26 ppm), CD3OD (H 3.30 ppm) orDMSO-d6 (H 2.49 ppm) were used as internal references.

Unless otherwise stated, starting materials were commercially availableor previously described in the literature. All solvents and commercialreagents were of laboratory grade and were used as received unlessotherwise stated.

Chemical names are preferably IUPAC names which were generated using ACDLabs 2014, or ChemDraw Ultra version 11.0.

General Experimental Details for Comparative Example 1:

Commercially available reagents and solvents (HPLC grade) were usedwithout further purification. ¹H NMR spectra were recorded on a BrukerDRX 500 MHz spectrometer or a Bruker DPX 250 MHz spectrometer indeuterated solvents. Chemical shifts (δ) are in parts per million.

Analytical HPLC-MS (METCR1673), was performed on Shimadzu LCMS-2010EVsystems using reverse phase Supelco Ascentis Express (2.7 μm, 2.1×30mm), gradient 5-100% B (A=water/0.1% formic acid, B=acetonitrile/0.1%formic acid) over 1.6 minutes injection volume 3 μL, flow=1.0 mL/minute.UV spectra were recorded at 215 nm using a SPD-M20A photo diode arraydetector. Mass spectra were obtained over the range m/z 100 to 100 at asampling rate of 2 scans per second using a LCMS2010EV. Data wereintegrated and reported using Shimadzu LCMS-Solutions andPsiPortsoftware.

Alternatively, (MET-uHPLC-AB-101) analytical HPLC-MS were performed on aWaters Acquity UPLC system with Waters PDA and ELS detectors using aPhenomenexKinetex-XB C-18 column, (1.7 μM, 2.1 mm×100 mm at a columntemperature of 40° C., gradient 5-100% B (A=water/0.1% formic acid;B=acetonitrile/0.1% formic acid) over 5.3 minutes, then 100% B for 0.5minute, flow=0.6 mL/minute. UV spectra were recorded at 215 nm using aWaters Acquity photo diode array. Mass spectra were obtained over therange m/z 150 to 850 at a sampling rate of 5 scans per second using aWaters SQD. Data were integrated and reported using Waters MassLynx andOpenLynxsoftware.

EXAMPLE 1 Synthesis of4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]-7-fluoro-1H-indol-1-yl]benzoicacid (Compound 1)

Step 1:

7-fluoro-1H-indole (1.5 g, 11.10 mmol), 4-iodobenzoic acid (2.75 g,11.10 mmol), 2-methylquinolin-8-ol (0.088 g, 0.55 mmol), copper(I)iodide (0.317 g, 1.66 mmol) were mixed as solids and diluted in DMSO (25mL). potassium carbonate (4.60 g, 33.30 mmol) was added and the mixturewas degassed by bubbling nitrogen for 15 mins. The mixture was stirredat 90° C. for 2 days. The mixture was partitioned between 4 M HCl (45mL) and ethyl acetate (200 ml). The layers were separated and theorganic layer was washed with water (2×10 mL). The organic layer waspassed through a phase separator and concentrated under reduced pressureuntil some 30 mL solvent remained. The mixture was filtered to give theproduct as a brown solid (1.38 g, 48%).

MS ESI⁻ [M-H]⁻ 254.1

Step 2:

4-(7-fluoro-1H-indol-1-yl)benzoic acid (1.38 g, 5.41 mmol) was mixedwith dichloromethane (25 mL) under an atmosphere of nitrogen.dimethylaluminum chloride (10.81 mL, 10.81 mmol) was added slowly whilecooling the mixture in an ice bath. 2-chloro-6-(trifluoromethyl)benzoylchloride (1.051 mL, 6.49 mmol) was added dropwise during 15 mins. Themixture was left for 15 mins with cooling and then quenched by additionof 4M HCl (15 mL). The mixture was partitioned between ethyl acetate(200 mL) and brine (30 ml). 15 mL of THF helped to clear layers. Thelayers were separated and the organic layer was washed with brine (3×30mL). The organic layer was passed through a phase separator andconcentrated under reduced pressure.

The material was purified by reverse phase HPLC Kromasil C8, 50×250 mm,linear gradient of 35-75% acetonitrile in water/acetonitrile/formic acid(95/5/0.2). The product fractions were pooled and concentrated underreduced pressure. The formed solid was collected by filtration andazeotroped with ethyl actate. The solid was dissolved in refluxingtoluene (appr. 40 mL) and the solution was slowly allowed to cool andstirred overnight. The mixture was filtered to give the product as awhite solid (0.850 g, 34%).

¹H NMR (500 MHz, CD₂Cl2) δ 7.11-7.2 (m, 1H), 7.36-7.50 (m, 2H),7.57-7.66 (m, 3H), 7.73-7.8 (m, 2H), 8.19-8.27 (m, 2H).

Expected Number of Hs: 12

Assigned Hs: 10.

Purity>99%, HRMS (C₂₃H₁₂ClF₄NO₃+H), expected 462.0515, observed462.0504.

COMPARATIVE EXAMPLE 2 Synthesis of4-[7-fluoro-3-[2-fluoro-6-(trifluoromethyl)benzoyl]-1-H-indol-1-yl]benzoicacid (Comparator Compound 2)

4-([-7-fluoro]-1H-indol-1-yl)benzoic acid (0.11 mmol) was dissolved indichloromethane (0.5 mL) and dimethylaluminum chloride (1M in hexanes)(0.211 mL, 0.21 mmol) was added. 2-fluoro-4-trifluoromethylbenzoylchloride (0.21 mmol), dissolved in dichloromethane (0.5 mL), was addedand the resulting mixture was stirred at ambient temperature for 30mins. The mixture was partitioned between 4 M HCl (2 mL) anddichloromethane (5 mL). The water layer was extracted withdichloromethane (2×5 mL) and the combined organic layer was passedthrough a phase separator. The organic layer was concentrated underreduced pressure. The residue was dissolved in DMSO (1 mL), filtered andpurified by reverse phase HPLC to give the product (yield 32%)

1H NMR (600 MHz, DMSO) δ 7.25 (m, 1H), 7.40 (m, 1H), 7.67-7.76 (m, 4H),7.76-7.82 (m, 1H), 8.02-8.07 (m, 2H), 8.07-8.19 (broad s, 1H), 8.29 (s,1H).

Expected Number of Hs: 12

Assigned Hs: 11.

EXAMPLE 3 Synthesis of4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]-7-fluoro-indol-1-yl]-2-hydroxy-benzoicacid (Compound 2)

This compound was made using a method similar to that described abovefor Comparator Compound 2, yield 36%.

1H NMR (600 MHz, DMSO) δ 6.87 (d, 1H), 6.91 (s, 1H), 7.06 (s, 1H), 7.14(s, 1H), 7.22 (t, 2H), 7.37 (s, 1H), 7.74 (t, 1H), 7.80 (d, 1H), 7.89(m, 2H), 8.10 (s, 1H), 8.20.

EXAMPLE 4 Synthesis of4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]-7-fluoro-indol-1-yl]-3-fluoro-benzoicacid (Compound 3)

This compound was made using a method similar to that described abovefor Comparator Compound 2, yield 20%.

1H NMR (600 MHz, DMSO) δ 7.24 (m, 1H), 7.39 (s, 1H), 7.76 (q, 1H), 7.82(d, 1H), 7.86-7.94 (m, 4H), 8.22 (s, 2H).

Expected Number of Hs: 11

Assigned Hs: 10.

COMPARATIVE EXAMPLE 5 Synthesis of3-fluoro-4-[7-fluoro-3-[2-fluoro-6-(trifluoromethyl)benzoyl]-1H-indol-1-yl]benzoicacid (Comparator Compound 5)

This compound was made using a similar method to that described abovefor Comparative Example 2, yield 39%.

¹H NMR (600 MHz, DMSO) δ 7.22-7.27 (m, 1H), 7.37-7.43 (m, 1H), 7.7-7.96(m, 7H), 8.11 (broad s), 8.31 (s, 1H).

EXAMPLE 6 Synthesis of4-[3-(2-chloro-6-cyclopropyl-benzoyl)-7-fluoro-1H-indol-1-yl]-3-fluoro-benzoicacid (Compound 4)

This compound was made using a similar method to that described abovefor Comparative Example 2, yield 80%.

1H NMR (600 MHz, DMSO) δ 0.64 (d, 1H), 0.76 (m, 2H), 0.82-0.91 (m, 1H),1.73 (m, 1H), 7.01 (d, 1H), 7.22 (m, 1H), 7.28-7.43 (m, 3H), 7.83 (t,1H), 7.87-7.94 (m, 2H), 8.04 (s, 2H).

Expected Number of Hs: 16

Assigned Hs: 15.

COMPARATIVE EXAMPLE 7 Synthesis of4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]-1H-indol-1-yl]benzoic acid(Comparator Compound 1)

This compound was synthesised using a similar method to that used forCompound 1.

¹H NMR (500 MHz, DMSO-d6) δ 13.19 (s, 1H), 8.53-8.18 (m, 2H), 8.15-8.07(m, 2H), 8.00-7.84 (m, 2H), 7.83-7.62 (m, 4H), 7.41 (s, 2H).

COMPARATIVE EXAMPLE 8 Synthesis of4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]-1H-indol-1-yl]benzoicSynthesis 4-[3-(2,6-dichlorobenzoyl)-7-fluoro-1H-indol-1-yl]benzoic acid(Comparator Compound 3)

This compound was made using a method similar to that described abovefor Compound 2, yield 22%.

1H NMR (600 MHz, DMSO) δ 7.25 (m, 1H), 7.40 (m, 1H), 7.54 (m, 1H),7.57-7.62 (m, 2H), 7.71 (m, 2H), 8.01-8.15 (m, 2H+hump 1H), 8.23 (s,1H), 13.23 (s, 1H).

COMPARATIVE EXAMPLE 9 Synthesis of4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]-1H-indol-1-yl]benzoicSynthesis of4-[3-(2,6-dichlorobenzoyl)-7-fluoro-1H-indol-1-yl]-3-fluoro-benzoic acid(Comparator Compound 4)

This compound was made using a method similar to that described abovefor Compound 2, yield 50%.

1H NMR (600 MHz, DMSO) δ 7.18-7.29 (m, 1H), 7.39 (m, 1H), 7.54 (m, 1H),7.60 (m, 2H), 7.84 (t, 1H), 7.88 (s, 2H), 8.08 (s, 1H), 8.26 (s, 1H).

Expected Number of Hs: 11

Assigned Hs: 10.

Biological Examples EXAMPLE 12 FRET Assay

This assay measures the binding of the SRC-1 peptide to the RORγ ligandbinding domain in the presence and absence of compound. The SRC-1peptide was tagged with the streptavidin-europium and the RORγ ligandbinding domain was tagged with strepavidin-APC. Labelled RORγ ligandbinding domain (50 nM) and SRC-1 peptide (80 nM) were incubated inbuffer containing 50 mM MOPS pH7.4, 50 mM potassium fluoride, 50 μMCHAPS (0.003% |), 0.1 mg/ml BSA (0.01%) and 50 mM DTT for 1 hour in thedark at room temperature n the presence and absence of compound.

Inverse agonists of coactivator binding will prevent a proximity basedenergy transfer between from Eu to APC resulting in decrease in the FRETsignal when measured at 665 nM.

Assay Protocol

The assay was run in black 384 well plates (Greiner cat no: 784900).Various concentrations of test ligands in 0.1 microliters DMSO weredispensed to assay plates using an Labcyte Echo acoustic dispenser. Twopre-mixes were prepared and incubated for 1 hr at room temp in the dark.Pre-mix 1 comprised 100 nM Protein (Biotinylated HN-Avi-MBP-TCS-hRORg(258-518)) and 60 nM Streptavidin APC in assay buffer, 50 mM MOPS pH7.4,50 mM KF, 0.003% (w/v) CHAPS, 10 mM DTT and 0.01% (w/v) BSA and pre-mix2 comprised 160 nM biotinylated SRC-1 peptide (NCOA1-677-700) and 20 nMEuropium-W8044 labelled Streptavidin in assay buffer. Five microlitersof pre-mix 2 was dispensed to assay plates containing test compound andincubated for 15 minutes prior to adding five microliters of pre-mix 1.Plates were incubated at room temperature for 1 hour in the dark, priorto reading in a Pherastar multi-mode plate reader using HTRF filter set(ex 320, em 612 and 665). The FRET signal at 665 nM was divided by thesignal at 612 nM and multiplied by 10,000 to generate a signal ratiovalue for each well. The raw data was transformed to % effect using theequation:Compound % effect=100*[(X−min)/(max−min)],where X represents the normalized value for the compound based on theMin (vehicle) and Max (reference compound) inhibition control.

The concentration of test ligand that inhibited the activity by 50%(i.e., the IC₅₀) was calculated by plotting the % effect versus testligand concentration and fitting the data using the Genedata ScreenerSmart fit algorithm.

The results for Compounds 1-14 are shown in Table 1.

TABLE 1 Mean IC₅₀ values for compounds in RORγ FRET assay Compound NoRORγ FRET - Mean IC₅₀ (nM) 1 43.62 2 17.92 3 37.86 4 42.94 Comparator 197.4 Comparator 2 61.92 Comparator 3 91.63 Comparator 4 59.61 Comparator5 110.7

EXAMPLE 13 Human Th17 Cell Differentiation Assay

Human CD4+CCR6+ T cells were isolated from peripheral blood mononuclearcells by positive selection. These cells were incubated in a cocktail ofcytokines (1 ng/mL TGF-β1, 10 ng/mL IL-1β, 50 ng/mL IL-23, 10 ng/mL IL-6and 5 ng/mL IL-2) and antiCD2/CD3/28 beads to induce polarisation andexpansion of CD4+ IL-17+ T cells (T_(H)17 cells) over a period of 4 daysin the presence and absence of compound.

The concentration of IL17A were measured in the extracellular media bysandwich ELISA. Compounds that inhibited T_(H)17 cell differentiationand expansion reduced the levels of IL-17A in the extracellular media.

The results are shown in Table 2.

TABLE 2 Mean IC₅₀ values for compounds in T_(H)17 cell differentiationassay Inhibition of T_(H)17 cell differentiation - Compound No Mean IC₅₀(nM) 1 19.79 2 12.59 3 15.04 4 31.9 Comparator 1 45.31 Comparator 248.22 Comparator 3 90.77 Comparator 4 71.31 Comparator 5 47

Several conclusions can be drawn from the results presented in Tables 1and 2.

As can be seen from a comparison of the results for Compound 1 andComparator Compound 1, the presence of the F at the 7-position of theindole ring greatly increases the activity.

Furthermore, compounds in which R² is trifluoromethyl are significantlymore active than similar compounds in which there is a chloro at thisposition. This can be seen from a comparison of the results for Compound1 with those for Comparator Compound 3 or the results for Compound 3with those for Comparator Compound 4 Compounds in which R² iscyclopropyl are also more active than compounds with a chloro in thisposition as shown by comparing the results for Compound 4 with those forComparator Compound 4.

Compounds of the present invention which have a chloro group at the2-position of the ring attached to the indole 3-position are more activethan compounds with a fluoro group in this position. This can be seenfrom a comparison of the results for Compound 1 with those of ComparatorCompound 2 or the results for Compound 3 with those for ComparatorCompound 5.

EXAMPLE 14 Oral Pharmacokinetics in Rats

Compound 1 was administered to rats intravenously at a dose of 0.47mg/kg and orally at a dose of 2.5 mg/kg. Compound 1 was well absorbedafter oral administration (F %=61%) and had achieved high plasma levels(Cmax=1.8 μM). The plasma concentrations were sustained for severalhours (t_(1/2) after intravenous administration was 5.1 hours andt_(1/2) after oral administration was 6.4 hours).

The invention claimed is:
 1. A pharmaceutical composition comprising apharmaceutically or veterinarily acceptable excipient and a compound offormula (I):

wherein: R¹ is selected from the group consisting of H, F and OH; R² isselected from the group consisting of C₁₋₃ alkyl, C₁₋₃ haloalkyl andcyclopropyl; provided that, when R¹ is H, R² is C₁₋₃ haloalkyl; or apharmaceutically or veterinarily acceptable salt, solvate or hydratethereof, a deuterated or tritiated derivative thereof, or a stereoisomerthereof; wherein the pharmaceutical composition is orally bioavailable.2. The pharmaceutical composition of claim 1, wherein in (I) R¹ is H. 3.The pharmaceutical composition of claim 1 wherein in (I) R² istrifluoromethyl.
 4. A pharmaceutical composition comprising apharmaceutically acceptable excipient and4-{3-[2-chloro-6-(trifluoromethyl)benzoyl]-7-fluoro-1H-indol-1-yl}benzoic acid (Compound 1), or apharmaceutically or veterinarily acceptable salt, solvate or hydratethereof, a deuterated or tritiated derivative thereof, or a stereoisomerthereof wherein the pharmaceutical composition is orally bioavailable.5. A method of treating a disease or condition mediated by RORγt, themethod comprising administering orally to a patient in need of suchtreatment a pharmaceutical composition comprising a pharmaceutically orveterinarily acceptable excipient and a compound of formula (I):

wherein: R¹ is selected from the group consisting of H, F and OH; R² isselected from the group consisting of C₁₋₃ alkyl, C₁₋₃ haloalkyl andcyclopropyl; provided that, when R¹ is H, R² is C₁₋₃ haloalkyl; or apharmaceutically or veterinarily acceptable salt, solvate or hydratethereof, a deuterated or tritiated derivative thereof, or a stereoisomerthereof; wherein the pharmaceutical composition is orally bioavailable,and wherein the disease or condition mediated by RORγt is at least oneselected from the group consisting of asthma, chronic obstructivepulmonary disease (COPD), bronchitis, allergic diseases, cysticfibrosis, lung allograft rejection, multiple sclerosis, rheumatoidarthritis, juvenile rheumatoid arthritis, osteoarthritis, ankylosingspondylitis, systemic lupus erythematosus, psoriasis, Hashimoto'sdisease, pancreatitis, autoimmune diabetes, autoimmune ocular disease,ulcerative colitis, Crohn's disease, inflammatory bowel disease (IBD),Sjorgen's syndrome, Behcet's disease, optic neuritis, type I diabetes,neuromyelitis optica, myasthenia gravis, uveitis, Guillain-Barresyndrome, psoriatic arthritis, Graves' disease, and scleritis.
 6. Amethod of treating a disease or condition mediated by RORγt, the methodcomprising administering orally to a patient in need of such treatment apharmaceutical composition comprising a pharmaceutically acceptableexcipient and 4-{3-[2-chloro-6-(trifluoromethyl)benzoyl]-7-fluoro-1H-indol-1-yl}benzoic acid (Compound 1), or apharmaceutically or veterinarily acceptable salt, solvate or hydratethereof, a deuterated or tritiated derivative thereof, or a stereoisomerthereof; wherein the pharmaceutical composition is orally bioavailable,and wherein the disease or condition mediated by RORγt is at least oneselected from the group consisting of asthma, chronic obstructivepulmonary disease (COPD), bronchitis, allergic diseases, cysticfibrosis, lung allograft rejection, multiple sclerosis, rheumatoidarthritis, juvenile rheumatoid arthritis, osteoarthritis, ankylosingspondylitis, systemic lupus erythematosus, psoriasis, Hashimoto'sdisease, pancreatitis, autoimmune diabetes, autoimmune ocular disease,ulcerative colitis, Crohn's disease, inflammatory bowel disease (IBD),Sjorgen's syndrome, Behcet's disease, optic neuritis, type I diabetes,neuromyelitis optica, myasthenia gravis, uveitis, Guillain-Barresyndrome, psoriatic arthritis, Graves' disease, and scleritis.